Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 15/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 15/20 | 1.00 |
| ▸ | NQO2 | P16083 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26989688 | 0.89 | MTNR1A (0.80) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL7894816 | 0.89 | MTNR1A (0.80) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL7894811 | 0.83 | MTNR1A (0.71) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1311849 | 0.81 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL7894801 | 0.79 | MTNR1A (0.65) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL1311579 | 0.78 | MTNR1A (0.70) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL7888641 | 0.77 | MTNR1A (0.62) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1310030 | 0.77 | MTNR1A (0.66) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL2858051 | 0.77 | MTNR1A (0.62) | MTNR1AMTNR1BNQO2KDM4EALDH1A1 | |
| SCHEMBL31543690 | 0.76 | MTNR1A (0.72) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5552428-A | ANTIARRHYTHMIA AGENTS FOR CARDIOVASCULAR DISORDERS USING MELATONIN DERIVATIVES | INSTITUTO FARMACOLOGICO LOMBARDO-IFLO, S.A.S. (IT) | 1996-09-03 | — | — | US | claimed |
| US-20090005430-A1 | Receptor Blocker and Vasodilator Comprising Indole Derivative as Active Ingredient | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2009-01-01 | — | — | US | disclosed |
| US-5763471-A | TREATS PSYCHIATARIC AND BRAIN DISORDERS | CEMAF (FR) | 1998-06-09 | — | — | US | disclosed |
| EP-0754183-A1 | NOVEL SPIRO[INDOLE-PYRROLIDINE] DERIVATIVES AS MELATONINERGIC AGONISTS, METHOD FOR PREPARING SAME AND USE THEREOF AS A DRUG | CEMAF (FR) | 1997-01-22 | — | — | EP | disclosed |
| US-5552428-A | ANTIARRHYTHMIA AGENTS FOR CARDIOVASCULAR DISORDERS USING MELATONIN DERIVATIVES | INSTITUTO FARMACOLOGICO LOMBARDO-IFLO, S.A.S. (IT) | 1996-09-03 | — | — | US | disclosed |
| WO-1995027712-A1 | NOVEL SPIRO[INDOLE-PYRROLIDINE] DERIVATIVES AS MELATONINERGIC AGONISTS, METHOD FOR PREPARING SAME AND USE THEREOF AS A DRUG | CEMAF (FR) | 1995-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005430-A1 | Receptor Blocker and Vasodilator Comprising Indole Derivative as Active Ingredient | ADRB2, ADRB1, ADRA2B | MTNR1A 261/4885MTNR1B 180/4885NQO2 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.